FILTER
FILTERED INTERVIEW RESULTS
Martin Toscano
MANAGING DIRECTOR, EVONIK INDUSTRIES (MEXICO)
Evonik Mexico benefits from the country’s increasingly export-based economy.
Marco Salcedo
DIRECTOR, AMVAC MÉXICO
AMVAC Mexico explains how it is growing through developing its portfolio with a particular emphasis on biological products.
Dr. Paul Kau
EHS TECHNICAL DIRECTOR FOR ASIA, GOLDER ASSOCIATES, SINGAPORE
Golder Associates in Singapore comment on the longer term implications of the pandemic on businesses and how environmental, health and safety concerns have come to the fore.
Alfredo Ison
EXECUTIVE PRESIDENT, QUÍMICA DELTA
Química Delta explains how Mexico’s chemical distribution market has fared throughout the current difficult period.
Patricio Cueva
GENERAL MANAGER, REACCIONES QUÍMICAS
Reacciones Químicas explains how it is preparing for new regulations restricting the use of VOCs in Coatings in Mexico and how the pandemic has impacted the market.
Gabriel Rodríguez Garrido
EXECUTIVE DIRECTOR, IPA
The Argentinian Petrochemical Institute (IPA) explains the current state of the industry.
Pedro Manrique & Felipe Trujillo
VP COMMERCIAL AND MARKETING & MANAGER PRODUCTS AND PETROCHEMICALS, ECOPETROL
Ecopetrol is expanding production in Colombia negating the need for certain imports.
Claudio Gorichon
CEO, GRUPO RENO S.A.
Reno distributes solvents in Chile and, more recently, Argentina and Peru.
German Torres
CEO, BRENNTAG LATIN AMERICA
“The two challenges of digitalization are how to manage the substantial high number of transactions and how to manage the distribution channels. Having a nice website or platform is useless if you cannot deliver.”
Juan Moncada
MANAGING DIRECTOR LATIN AMERICA, EASTMAN
Eastman Latin America has maintained profitability during H1 2020 and continues introducing new sustainable products.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
